دورية أكاديمية
أعرض في EDS

Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.

التفاصيل البيبلوغرافية
العنوان: Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis.
المؤلفون: McDonald OG; Department of Pathology, Microbiology and Immunology, Vanderbilt-Ingram Cancer Center, and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Li X; Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Saunders T; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Tryggvadottir R; Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Mentch SJ; Duke Cancer Institute, Duke Molecular Physiology Institute, Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA., Warmoes MO; Duke Cancer Institute, Duke Molecular Physiology Institute, Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA., Word AE; Department of Pathology, Microbiology and Immunology, Vanderbilt-Ingram Cancer Center, and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Carrer A; Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Salz TH; Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Natsume S; Department of Pathology, Microbiology and Immunology, Vanderbilt-Ingram Cancer Center, and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Stauffer KM; Department of Pathology, Microbiology and Immunology, Vanderbilt-Ingram Cancer Center, and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Makohon-Moore A; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Zhong Y; Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wu H; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA., Wellen KE; Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Locasale JW; Duke Cancer Institute, Duke Molecular Physiology Institute, Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA., Iacobuzio-Donahue CA; Departments of Pathology and Human Oncology and Pathogenesis Program, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Feinberg AP; Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Departments of Medicine, Biomedical Engineering and Mental Health, Johns Hopkins University Schools of Medicine, Engineering and Public Health, Baltimore, Maryland, USA.
المصدر: Nature genetics [Nat Genet] 2017 Mar; Vol. 49 (3), pp. 367-376. Date of Electronic Publication: 2017 Jan 16.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Co Country of Publication: United States NLM ID: 9216904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1718 (Electronic) Linking ISSN: 10614036 NLM ISO Abbreviation: Nat Genet Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Nature Pub. Co., c1992-
مواضيع طبية MeSH: Epigenesis, Genetic/*genetics , Glucose/*metabolism , Neoplasm Metastasis/*genetics , Pancreatic Neoplasms/*genetics, Carcinogenesis/genetics ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/metabolism ; Chromatin/genetics ; Epigenomics/methods ; Gene Expression/genetics ; Heterochromatin/genetics ; Histones/genetics ; Humans ; Pancreatic Neoplasms/metabolism
مستخلص: During the progression of pancreatic ductal adenocarcinoma (PDAC), heterogeneous subclonal populations emerge that drive primary tumor growth, regional spread, distant metastasis, and patient death. However, the genetics of metastases largely reflects that of the primary tumor in untreated patients, and PDAC driver mutations are shared by all subclones. This raises the possibility that an epigenetic process might operate during metastasis. Here we report large-scale reprogramming of chromatin modifications during the natural evolution of distant metastasis. Changes were targeted to thousands of large chromatin domains across the genome that collectively specified malignant traits, including euchromatin and large organized chromatin histone H3 lysine 9 (H3K9)-modified (LOCK) heterochromatin. Remarkably, distant metastases co-evolved a dependence on the oxidative branch of the pentose phosphate pathway (oxPPP), and oxPPP inhibition selectively reversed reprogrammed chromatin, malignant gene expression programs, and tumorigenesis. These findings suggest a model whereby linked metabolic-epigenetic programs are selected for enhanced tumorigenic fitness during the evolution of distant metastasis.
التعليقات: Comment in: Nat Rev Cancer. 2017 Feb 23;17 (3):141. (PMID: 28228644)
Comment in: Cancer Cell. 2017 Mar 13;31(3):309-310. (PMID: 28292434)
References: Nat Rev Genet. 2016 May;17(5):284-99. (PMID: 26972587)
Cancer Biol Ther. 2005 May;4(5):548-54. (PMID: 15846069)
Cancer Cell. 2014 Mar 17;25(3):379-92. (PMID: 24613412)
J Biol Chem. 2003 Jan 17;278(3):1824-30. (PMID: 12435727)
BMC Genomics. 2012 Oct 26;13:566. (PMID: 23102236)
FEBS Lett. 1970 Feb 16;6(3):225-228. (PMID: 11947380)
Nat Genet. 2009 Feb;41(2):246-50. (PMID: 19151716)
Nature. 2015 Feb 19;518(7539):413-6. (PMID: 25487152)
Nat Genet. 2011 Jun 26;43(8):768-75. (PMID: 21706001)
Nature. 2010 Oct 28;467(7319):1109-13. (PMID: 20981101)
Cancer Res. 1986 Nov;46(11):5810-5. (PMID: 3019537)
Cell. 2007 Feb 23;128(4):693-705. (PMID: 17320507)
Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168)
J Clin Oncol. 2009 Apr 10;27(11):1806-13. (PMID: 19273710)
Cell Metab. 2015 Nov 3;22(5):861-73. (PMID: 26411344)
Science. 2002 Sep 27;297(5590):2232-7. (PMID: 12215653)
Genome Biol. 2009;10(3):R25. (PMID: 19261174)
Bioinformatics. 2011 Mar 15;27(6):870-1. (PMID: 21325299)
Nat Med. 2010 Dec;16(12):1450-5. (PMID: 21102459)
Genome Biol. 2012 Oct 03;13(10):R83. (PMID: 23034175)
Gastroenterology. 2011 Dec;141(6):2218-2227.e5. (PMID: 21864475)
Genome Res. 2012 Sep;22(9):1813-31. (PMID: 22955991)
Trends Biochem Sci. 2016 Mar;41(3):211-218. (PMID: 26778478)
Mol Cell. 2014 Aug 21;55(4):552-65. (PMID: 25042803)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Mol Cell. 2003 Dec;12(6):1591-8. (PMID: 14690610)
Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647)
Cancer Metab. 2015 Sep 23;3:10. (PMID: 26401273)
Nat Struct Mol Biol. 2011 Jul 03;18(8):867-74. (PMID: 21725293)
Genome Biol. 2010;11(10):R106. (PMID: 20979621)
Cancer Cell. 2013 Jun 10;23(6):725-38. (PMID: 23707782)
Cancer Res. 1982 Feb;42(2):601-8. (PMID: 7034925)
Genome Biol. 2008;9(9):R137. (PMID: 18798982)
Cell Metab. 2014 Aug 5;20(2):306-319. (PMID: 24998913)
In Vitro. 1982 Jan;18(1):24-34. (PMID: 7182348)
Science. 2009 May 22;324(5930):1076-80. (PMID: 19461003)
Bioinformatics. 2012 Jul 15;28(14):1933-4. (PMID: 22592379)
Science. 1955 Oct 28;122(3174):834. (PMID: 17780783)
PLoS Comput Biol. 2012 May;8(5):e1002529. (PMID: 22693437)
Genome Med. 2014 Aug 26;6(8):61. (PMID: 25191524)
Genome Res. 2012 Feb;22(2):246-58. (PMID: 22156296)
Science. 2008 Sep 26;321(5897):1801-6. (PMID: 18772397)
Nature. 2010 Oct 28;467(7319):1114-7. (PMID: 20981102)
Cell. 2013 Mar 28;153(1):56-69. (PMID: 23540690)
Anal Chem. 2014 Feb 18;86(4):2175-84. (PMID: 24410464)
Cell Stem Cell. 2010 May 7;6(5):479-91. (PMID: 20452322)
Cell Cycle. 2012 Mar 15;11(6):1151-66. (PMID: 22377695)
معلومات مُعتمدة: F31 CA180682 United States CA NCI NIH HHS; R01 CA179991 United States CA NCI NIH HHS; P30 DK058404 United States DK NIDDK NIH HHS; R00 CA168997 United States CA NCI NIH HHS; R01 CA054358 United States CA NCI NIH HHS; P50 CA095103 United States CA NCI NIH HHS; R01 CA140599 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Chromatin)
0 (Heterochromatin)
0 (Histones)
IY9XDZ35W2 (Glucose)
تواريخ الأحداث: Date Created: 20170117 Date Completed: 20170905 Latest Revision: 20220331
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC5695682
DOI: 10.1038/ng.3753
PMID: 28092686
قاعدة البيانات: MEDLINE
الوصف
تدمد:1546-1718
DOI:10.1038/ng.3753